The Food and Drug Administration commissioner Robert Califf began a marathon meeting on regulation of generative artificial intelligence this week with an urgent warning. He said clinicians around the country had told him the technology’s adoption in their hospitals and clinics was being driven by financial considerations — not patient care.
“Unless you take this issue very seriously and form alliances with those concerned about improving health outcomes,” Califf cautioned, “this technology will improve profits at the cost of continued deterioration in our overall health status.”
The sobering statement was the prelude to a two-day meeting during which one of the world’s most influential regulatory bodies sought to get its arms around one of the world’s most powerful, and unpredictable, technologies. It also unfolded amid the transition to an incoming Trump administration that may hold starkly different views about AI, and pursue its own course in regulating the technology in medicine and other parts of the economy.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in